Trial Profile
Clinical study for effect and safety, as well as prognostic factors analysis of apapitatin mesylate combined with TACE in the treatment of patients with advanced hepatocellular carcinoma
Status:
Not yet recruiting
Phase of Trial:
Phase IV
Latest Information Update: 07 Aug 2018
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 07 Aug 2018 New trial record